Hypertension
Conditions
Interventions
Group 1:1 tablet of levamlodipine besylate (2.5mg) and 1 tablet of bisoprolol fumarate (2.5mg), taken daily in the morning once a day for 26 weeks ± 2 weeks continuously
Group 2:1 tablet of levamlodipine besylate (2.5mg) and 1 tablet of bisoprolol fumarate (5mg), taken daily in the morning once a day for 26 weeks ± 2 weeks continuously
Sponsors
Sichuan Provincial People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: (1) According to the diagnostic criteria of the Chinese Guidelines for the Prevention and Treatment of Hypertension (revised in 2018), patients diagnosed with primary hypertension; (2) Currently receiving treatment with 2.5mg levamlodipine besylate tablets combined with 2.5mg bisoprolol fumarate tablets or 2.5mg levamlodipine besylate tablets combined with 5mg bisoprolol fumarate tablets; (3) Voluntarily participate and sign an informed consent form.
Exclusion criteria
Exclusion criteria: (1) Known allergy to levamlodipine, amlodipine, and bisoprolol; (2) Pregnancy test positive, lactating women, or subjects with fertility plans during the study period; (3) Patients with known contraindications of levamlodipine, amlodipine, or bisoprolol, such as second or third degree atrioventricular block (without a pacemaker installed), sick sinus syndrome, sinus block, severe bronchial asthma, severe chronic obstructive pulmonary disease, advanced peripheral arterial obstructive disease, Raynaud's syndrome, untreated pheochromocytoma, metabolic acidosis, psoriasis, etc.
Countries
China
Contacts
Public ContactYan Shu
Sichuan Provincial People's Hospital
Outcome results
None listed